NOS3 and endothelial dysfunction: In in vivo and in vitro studies, blockade of the expression of A-FABP by an inhibitor or by the knockout method revealed that A-FABP might contribute to endothelial dysfunction or atherosclerosis through alteration of inflammatory cytokine production or modulation of the activation of endothelial nitric oxide synthase [32,33].